Doxazosin → Terazosin

反応式

[CH3:1][O:2][C:3]1[CH:4]=[C:5]2[C:14]([NH2:15])=[N:13][C:12]([N:16]3[CH2:21][CH2:20][N:19]([C:22]([CH:24]4[O:33][C:32]5[CH:31]=CC=CC=5O[CH2:25]4)=[O:23])[CH2:18][CH2:17]3)=[N:11][C:6]2=[CH:7][C:8]=1[O:9][CH3:10].NC1C2C(=CC(OC)=C(OC)C=2)N=C(Cl)N=1>>[CH3:1][O:2][C:3]1[CH:4]=[C:5]2[C:14]([NH2:15])=[N:13][C:12]([N:16]3[CH2:21][CH2:20][N:19]([C:22]([CH:24]4[O:33][CH2:32][CH2:31][CH2:25]4)=[O:23])[CH2:18][CH2:17]3)=[N:11][C:6]2=[CH:7][C:8]=1[O:9][CH3:10]

参加物

反応物 2

HCID 3157Doxazosin

HCID 902352-Chloro-6,7-dimethoxy-4-quinazolinamine

生成物 1

HCID 5401Terazosin収率 73%

実験手順

The procedures were the same as described for Doxazosin, except that compound 3 (3.0 g, 16.3 mmol) prepared from Example 5 was reacted with 4-amino-2-chloro-6,7-dimethoxyquinazoline (3.8 g, 16.1 mmol) to provide 5.0 g of hydrochloride salt of Terazosin (73% yield), which is then converted to Terazosin (4.7 g, white solid) by alkalizing.

出典と根拠

ORDレコード: ord-361b0ecf32fe4ff3a887ee3db58d5702
出典データセット: uspto-grants-2001_11
DOI: 10.6084/m9.figshare.5104873.v1
特許番号: US06313294B1

反応ノート

読み込み中…